TEBOKAN Ginkgo Biloba Egb 761 40mg Film-Coated Tablet 20's
RXDRUG-DR-XY20680
Discreet Packaging
FDA-registered Products
FDA-licensed Pharmacies
Indications/Uses
For the treatment of disturbance in cerebral performance (decreasing intellectual capacity and vigilance) with the following symptoms: dizziness, tinnitus, headache, deficient memory, emotional instability w/ anxiety.
As supporting treatment for restricted hearing capacity due to cervical syndrome. For the treatment of peripheral arterial circulatory disturbance with maintenance of circulatory reserve (intermittent claudication).
For the symptomatic treatment of mental losses due to organic brain syndrome within the framework of general therapeutic concept for dementia syndrome having as major symptoms: deficient memory, disturbances of concentration, depressive mood, dizziness, tinnitus, headache.
As supporting treatment for restricted hearing capacity due to cervical syndrome. For the treatment of peripheral arterial circulatory disturbance with maintenance of circulatory reserve (intermittent claudication).
For the symptomatic treatment of mental losses due to organic brain syndrome within the framework of general therapeutic concept for dementia syndrome having as major symptoms: deficient memory, disturbances of concentration, depressive mood, dizziness, tinnitus, headache.
Dosage/Direction for Use
Unless otherwise prescribed, one tablet to be taken 3 times per day unchewed, with a small quantity of liquid.
Overdosage
There are no cases of overdose reported.
Administration
May be taken with or without food: Swallow whole, do not chew.
Contraindications
Do not take Ginkgo biloba EGb 761 (Tebokan): If the patient is allergic (hypersensitive) to Ginkgo biloba or to any of the other ingredients of Ginkgo biloba EGb 761 (Tebokan). Pregnancy: During pregnancy. There are no or limited amount of data from the use of Ginkgo biloba EGb 761 (Tebokan) in pregnant women. As a precautionary measure, it is preferable to avoid the use of Ginkgo biloba EGb 761 (Tebokan).
Lactation: As no sufficient investigations are available, this preparation should not be used during lactation. It is not known whether the extract components are excreted in human milk.
Fertility: Animal studies do not reveal harmful effects of Ginkgo biloba EGb 761 (Tebokan) on the fertility.
Lactation: As no sufficient investigations are available, this preparation should not be used during lactation. It is not known whether the extract components are excreted in human milk.
Fertility: Animal studies do not reveal harmful effects of Ginkgo biloba EGb 761 (Tebokan) on the fertility.
Use In Pregnancy & Lactation
Pregnancy: During pregnancy. There are no or limited amount of data from the use of Ginkgo biloba EGb 761 (Tebokan) in pregnant women. As a precautionary measure, it is preferable to avoid the use of Ginkgo biloba EGb 761 (Tebokan).
Lactation: As no sufficient investigations are available, this preparation should not be used during lactation. It is not known whether the extract components are excreted in human milk.
Lactation: As no sufficient investigations are available, this preparation should not be used during lactation. It is not known whether the extract components are excreted in human milk.
Adverse Reactions
There are no verified data on the frequency of the undesirable effects observed during treatment with Ginkgo biloba-containing preparations, since these undesirable effects have become known through single reports from patients, physicians or pharmacists. According to these reports, the following undesirable effects may occur during treatment with Ginkgo biloba EGb 761 (Tebokan): Gastrointestinal disorders: Mild gastrointestinal disturbances.
Skin and subcutaneous tissue disorders / Immune system disorders: Hypersensitivity reactions.
Nervous system disorders: Headache.
Vascular disorders: Bleeding from single organs has been reported.
Skin and subcutaneous tissue disorders / Immune system disorders: Hypersensitivity reactions.
Nervous system disorders: Headache.
Vascular disorders: Bleeding from single organs has been reported.
Drug Interactions
In case of simultaneous application of Ginkgo biloba EGb 761 (Tebokan) with coagulation-inhibiting drugs (such as phenprocoumon, warfarin, clopidogrel, acetylsalicylic acid and other non-steroidal antirheumatics) it cannot be excluded that the effect of these medicines is enhanced.
As for all medicinal preparations, it cannot be excluded that Ginkgo biloba EGb 761 (Tebokan) acts on the metabolization of different other medicinal preparations which may influence the potency and/or duration of the effect of the preparation concerned. There are not sufficient investigations available on these effects. Please tell the doctor or pharmacist if the patient is taking or have recently taken any other medicines, including medicines obtained without a prescription.
As for all medicinal preparations, it cannot be excluded that Ginkgo biloba EGb 761 (Tebokan) acts on the metabolization of different other medicinal preparations which may influence the potency and/or duration of the effect of the preparation concerned. There are not sufficient investigations available on these effects. Please tell the doctor or pharmacist if the patient is taking or have recently taken any other medicines, including medicines obtained without a prescription.
Storage
Store at temperatures not exceeding 25°C.
Action
Pharmacology: Properties: Based on a complicated patented manufacturing process, Ginkgo biloba EGb 761 (Tebokan) contains enriched active ingredients obtained from leaves of the Ginkgo tree. Ginkgo biloba EGb 761 (Tebokan) improves the flow properties of the blood and increases its flow rate, particularly the region of small and very small blood vessel. Both in the brain as well as in the arms and legs. Ginkgo biloba EGb 761 (Tebokan) produces an improvement in the supply of blood and oxygen to the tissue, and protects tissue cells from the damaging effects of lack in oxygen.
In case of disturbances of cerebral performance, Ginkgo biloba EGb 761 (Tebokan) improves decreasing intellectual capacity and vigilance, thus providing relief to accompanying symptoms such as dizziness, tinnitus, headache, deficient memory and emotional instability with anxiety.
Ginkgo biloba EGb 761 (Tebokan) increases hearing capacity in case of cervical syndrome.
Ginkgo biloba EGb 761 (Tebokan) produces a reduction in pain and unpleasant sensations with formication as well as a sensation of numbness and coldness accompanying circulatory disturbances in the limbs. In the case of intermittent claudication (walking pains) Ginkgo biloba EGb 761 (Tebokan) clearly extends the painfree walking distance. Ginkgo biloba EGb 761 (Tebokan) has no unfavorable influence on the carbohydrate metabolism and is therefore also suitable for diabetics.
Pharmacodyamics: The following pharmacological effects have been proven in animal experiments with the quantified extract of EGb 761 contained in Tebokan: Increased in tolerance to hypoxia, in particular of the cerebral tissue, inhibition of the development of traumatically or toxically induced brain edema and acceleration of its regression, reduction of retina edema and lesions of retina cells, inhibition of age-related reduction of muscarinergic choline receptors and alpha-2-adrenoceptors as well as promotion of choline intake in the hippocampus, enhancement of memory performance and learning capacity, improved compensation of disturbances of equilibrium, circulatory increase in particular in the region of microcirculation, improvement of rheological properties of the blood, inactivation of toxic oxygen radicals (flavonoids), PAF antagonism (ginkgolides) and neuroprotective effect (ginkgolides A and B, bilobalide).
Hypoxia-protective effects, increase of blood flow, in particular in the microcirculatory region and improvement of the rheological properties of the blood could be demonstrated in humans.
Pharmacokinetics: Cerebral bioavailability of the quantified extract EGb 761 in humans was demonstrated in the pharmaco-EEG on the base of dose-dependent effects on cerebro-electrical activity.
After oral application of 80mg Ginkgo extract, the terpene lactone ginkgolide A, ginkgolide B and bilobalide showed in humans a very good absolute bioavailability of 98% for ginkgolide A, 79% for ginkgolide B and 72% for bilobalide. Maximum plasma concentrations were 15 ng/ml for ginkgolide A, 4 ng/ml for ginkgolide B and approx. 12 ng/ml for bilobalide. Half-lives were 3.9 hours (ginkgolide A), 7 hours (ginkgolide B) and 3.2 hours (bilobalide).
Plasma-protein binding (human blood) is 43% for ginkgolide A, 47% for ginkgolide B and 67% for bilobalide.
In the rat, resorption rate of 60% was determined following oral administration of 14C radioactively tagged extract EGb 761. Maximum plasma concentrations were measured 1.5 hours after administration; half-life was 4.5 hours. A second plasma peak 12 hours after administration is indicative of an enterohepatic shunt.
In case of disturbances of cerebral performance, Ginkgo biloba EGb 761 (Tebokan) improves decreasing intellectual capacity and vigilance, thus providing relief to accompanying symptoms such as dizziness, tinnitus, headache, deficient memory and emotional instability with anxiety.
Ginkgo biloba EGb 761 (Tebokan) increases hearing capacity in case of cervical syndrome.
Ginkgo biloba EGb 761 (Tebokan) produces a reduction in pain and unpleasant sensations with formication as well as a sensation of numbness and coldness accompanying circulatory disturbances in the limbs. In the case of intermittent claudication (walking pains) Ginkgo biloba EGb 761 (Tebokan) clearly extends the painfree walking distance. Ginkgo biloba EGb 761 (Tebokan) has no unfavorable influence on the carbohydrate metabolism and is therefore also suitable for diabetics.
Pharmacodyamics: The following pharmacological effects have been proven in animal experiments with the quantified extract of EGb 761 contained in Tebokan: Increased in tolerance to hypoxia, in particular of the cerebral tissue, inhibition of the development of traumatically or toxically induced brain edema and acceleration of its regression, reduction of retina edema and lesions of retina cells, inhibition of age-related reduction of muscarinergic choline receptors and alpha-2-adrenoceptors as well as promotion of choline intake in the hippocampus, enhancement of memory performance and learning capacity, improved compensation of disturbances of equilibrium, circulatory increase in particular in the region of microcirculation, improvement of rheological properties of the blood, inactivation of toxic oxygen radicals (flavonoids), PAF antagonism (ginkgolides) and neuroprotective effect (ginkgolides A and B, bilobalide).
Hypoxia-protective effects, increase of blood flow, in particular in the microcirculatory region and improvement of the rheological properties of the blood could be demonstrated in humans.
Pharmacokinetics: Cerebral bioavailability of the quantified extract EGb 761 in humans was demonstrated in the pharmaco-EEG on the base of dose-dependent effects on cerebro-electrical activity.
After oral application of 80mg Ginkgo extract, the terpene lactone ginkgolide A, ginkgolide B and bilobalide showed in humans a very good absolute bioavailability of 98% for ginkgolide A, 79% for ginkgolide B and 72% for bilobalide. Maximum plasma concentrations were 15 ng/ml for ginkgolide A, 4 ng/ml for ginkgolide B and approx. 12 ng/ml for bilobalide. Half-lives were 3.9 hours (ginkgolide A), 7 hours (ginkgolide B) and 3.2 hours (bilobalide).
Plasma-protein binding (human blood) is 43% for ginkgolide A, 47% for ginkgolide B and 67% for bilobalide.
In the rat, resorption rate of 60% was determined following oral administration of 14C radioactively tagged extract EGb 761. Maximum plasma concentrations were measured 1.5 hours after administration; half-life was 4.5 hours. A second plasma peak 12 hours after administration is indicative of an enterohepatic shunt.
MedsGo Class
Peripheral Vasodilators & Cerebral Activators
Features
Brand
Tebokan
Full Details
Dosage Strength
40mg
Drug Ingredients
- Ginkgo Biloba
Drug Packaging
Film-Coated Tablet 20's
Generic Name
Ginkgo Biloba Egb 761
Dosage Form
Film-Coated Tablet
Registration Number
DR-XY20680
Drug Classification
Prescription Drug (RX)
Please sign in so that we can notify you about a reply